NCT04933669

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 122 (estimated)
• Sponsor: First Affiliated Hospital of Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. A few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.

Conditions

• Progression-free Survival
• Gastrointestinal Stromal Tumor
• Neoadjuvant

Interventions

Type	Name	Description
DRUG	Imatinib	Imatinib neoadjuvant therapy

Timeline

• Start date: 2021-09-07
• Primary completion: 2029-12-31
• Completion: 2029-12-31
• First posted: 2021-06-22
• Last updated: 2021-10-12

Locations

1 site across 1 country: China